ALMIRALL SA

Their core work

Almirall is a Barcelona-based pharmaceutical company with a strong focus on dermatology, developing treatments and diagnostic approaches for skin diseases such as atopic dermatitis and psoriasis. In H2020, they contribute clinical expertise and patient data to large research consortia investigating disease biomarkers, molecular profiling, and clinical trial data frameworks. They also have a secondary track in industrial chemistry, having participated in projects on process intensification and hybrid catalysis, likely connected to pharmaceutical manufacturing processes.

What they specialise in

How they've shifted over time

Almirall's H2020 trajectory shows a clear pivot from industrial chemistry toward health and pharma data sciences. Their earlier projects (2015-2018) focused on chemical process intensification and hybrid catalysis — likely tied to pharmaceutical manufacturing. From 2019 onward, they shifted decisively into dermatology research (BIOMAP) and clinical data ethics (FACILITATE), reflecting the company's well-known commercial focus on skin diseases. This evolution suggests Almirall used early H2020 participation to support manufacturing R&D, then strategically redirected EU collaboration toward their core therapeutic area.

Almirall is moving toward precision dermatology and responsible clinical data reuse, making them a strong partner for projects combining skin disease research with big data and regulatory compliance.

How they like to work

Almirall participates exclusively as a consortium partner — they have never coordinated an H2020 project. They join large consortia (96 unique partners across just 4 projects suggests average consortium sizes of 20+ members), contributing industry perspective and clinical resources rather than leading the research agenda. This makes them a reliable industrial partner who brings real-world pharmaceutical context without competing for project leadership.

Despite only 4 projects, Almirall has built a remarkably wide network of 96 unique partners across 21 countries, reflecting their participation in large-scale European health and manufacturing consortia. Their reach spans most of the EU, with no narrow geographic clustering.

What sets them apart

Almirall brings something rare to EU consortia: an established pharmaceutical company with direct commercial interest in dermatology, willing to contribute clinical expertise and patient access to collaborative research. Unlike academic partners, they can validate research outputs against real drug development pipelines. Their recent move into clinical data governance (FACILITATE) also positions them as an industry voice on ethical data reuse — valuable for any project navigating GDPR in health research.

Highlights from their portfolio

• BIOMAP
  Large-scale dermatology research project (2019-2025) combining deep phenotyping, single-cell analysis, and disease mapping for atopic dermatitis and psoriasis — directly aligned with Almirall's core business.
• FACILITATE
  Forward-looking project (2022-2026) on ethical and legal frameworks for clinical trial data reuse, positioning Almirall at the intersection of pharma and data governance.
• MULTI2HYCAT
  Almirall's only project with recorded EC funding (EUR 401,625), focused on hybrid catalysis for multi-step chemical processes.